Quantcast

Posts related to ‘AMRN’

Wall St Bull statue

12 Stocks Expected to Rise by 50% to 100% (or More) in 2013 (AMRN, CRZO, CNDO, EMKR, ETRM, EXAS, GALE, MX, OEDV, REGI, SPWR, SGYP)

It may seem hard to believe, but some stocks are expected to rise by 50%, 100%, or even more over the next year. Our own DJIA peak price target is ...
Read Full Story »
Bull and Bear figures

24/7 Wall St. Closing Bell — December 7, 2012: Markets Wobble to Mixed Close (TCK, MCD, SYT, AET, MPEL, HWD, PANW, SWHC, WGO, UEC, SMRT, SCHL, FGP, CMVT, AMRN, GRPN, F)

U.S. equity markets opened higher this morning following a poor growth forecast from Europe and a better-than-expected report on U.S. unemployment. The German central bank said this morning that Germany’s ...
Read Full Story »
pills

Amarin Takes on More Debt, Shares Suffer

Biopharmaceutical company Amarin Corp. PLC (NASDAQ: AMRN) announced after markets closed last night that it has received $100 million in nonequity financing from an investment fund managed by Pharmakon Advisors. ...
Read Full Story »

Top Analyst Upgrades and Downgrades (AMRN, BSX, BRCD, CVC, CFNL, CROX, FINL, FL, GMO, HMA, LAZ, NOV, OTEX, PCG, RH, SHOO, VPHM, YELP)

These are some of the top analyst upgrades, downgrades and initiations seen in Wall St. research calls this Tuesday. Amarin Corp. (NASDAQ: AMRN) started as Buy with $20 target at ...
Read Full Story »

Hot After-Hours Stocks on the Move (MDRX, AMRN, GRPN, KYAK, PCLN, EXPE,OWW, TRIP, LGF, MCP, PEGA, SPRD, ZIP)

We are tracking many key movers in the after-hours trading this Thursday. Most are earnings but some are not. Allscripts Healthcare Solutions Inc. (NASDAQ: MDRX) is up over 7% at $13.20 ...
Read Full Story »

Amarin Becomes A January 2013 Story on FDA Uncertainty

Amarin Corporation plc (NASDAQ: AMRN) is not exactly having a good day considering that its fish oil based drug for lowering triglycerides is not going to be a known event as soon ...
Read Full Story »

Amarin Shares Fall Despite Regulatory OK

Usually, shares of drug makers soar following the announcement that the Foood and Drug Administration approved a drug. Amarin Corp. (NASDAQ: AMRN) announced approval by the FDA for Vascepta to ...
Read Full Story »

Looking for the Next Biotech Buyout After Two Drug and Biotech Deals

What usually happens when you get two mergers announced in drugs and biotech in the same day? Investors begin to wonder which other peers and competitors might be on the ...
Read Full Story »

Finding the Next Biotech M&A Targets (HGSI, GSK, AMLN, BMY, VRTX, CELG, CBST, AMRN, DNDN, BMRN, VVUS, ARNA, PCYC, VICL, MDGN, AFFX, THRX, RIGL)

More biotech mergers are on the way! That is the verdict of Wall St. There may be patent protection risks associated with future regulation under health care, but deals in ...
Read Full Story »

Which Biotechs Could Be Next M&A Targets (AMLN, BMY, VRTX, CELG, CBST, AMRN, BMRN, VVUS, ARNA, PCYC, AFFX, THRX, RIGL, HGSI, GSK, DNDN)

The freshly announced multibillion biotech buyout of Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) for more than $5 billion in equity value may be a bit misleading if you consider that it ...
Read Full Story »

BioWatch: Amarin Joins Ten-Bagger Chase (AMRN)

Amarin Inc. (NASDAQ: AMRN) just went off the charts, literally.  The company reported very solid Phase III study results this morning and the stock is now up almost tenfold from ...
Read Full Story »

Best BioHealth Stocks of 2010, Outlook for 2011 (JAZZ, DNDN, HGSI, ARIA, AMRN, NBIX, THRX)

2010 has been an interesting year in biotech and in biohealth stocks, even if it has lacked some of the ten-baggers that were seen in 2009.  In 2009, companies like ...
Read Full Story »

10 Major Stock Movers For Monday (AMRN, AMAG, AIB, IRE, NBG, DRYS, NLST, ALU, RYAAY, VOLT)

Amarin Corporation plc (NASDAQ: AMRN) is indicated up 50% at $5.35, well above the $3.85 52-week high, after its AMR101 met pivotal phase 3 study endpoints with highly statistically significant ...
Read Full Story »